Secondary Logo

Journal Logo

Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission

Erratum

doi: 10.1097/01.aids.0000568920.95615.11
Erratum
Free

The authors of this article [1] report an error in the description of the methods for the antiretroviral (ARV) drugs used in the pharmacokinetic (PK) study in mice. The mice in the PK study of ARVs in solution received emtricitabine (FTC) in addition to tenofovir alafenamide (TAF) and elvitegravir (EVG) and this was not reported in the article. The mice in the PK study of ARVs in nanoformulation received only TAF+EVG. Finally, administration of ARVs in solution was not part of the approved IACUC approval (IACUC #0989). IACUC approval was for PK of ARV in the nanoformulation. The omission that the mice received these 3 drugs in solution, means that the legend for Fig. 2 is modified to include “with emtricitabine” in the description for Fig. 2b. and should be as follows:

Fig. 2. Antiretroviral drugs (TNF + elvitegravir) concentrations over time (three mice/time point) from administration in nanoparticles (a) or in solution (together with emtricitabine, b) were given 200 mg/kg per drug subcutaneously. Vaginal tissue samples were analyzed by LC–MS/MS.

Back to Top | Article Outline

Reference

1. Mandal S, Prathipati PK, Kang G, Zhou Y, Yuan Z, Fan W, et al. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS 2017; 31:469–476.
Copyright © 2019 Wolters Kluwer Health, Inc.